1. The efficacy and safety of ciclesonide for the treatment of perennial allergic rhinitis: a systematic review and meta-analysis
- Author
-
Wenbin Wu, Bin Li, Nan Xiang, Qi Yang, Dengpiao Xie, Fei Wang, Li He, and Yan Dong
- Subjects
medicine.medical_specialty ,Rhinitis, Allergic, Perennial ,Perennial plant ,Ciclesonida ,Ciclesonide ,Chronic inflammatory disease ,Placebo ,law.invention ,Metanálise ,03 medical and health sciences ,chemistry.chemical_compound ,Allergic ,0302 clinical medicine ,Randomized controlled trial ,Pregnenediones ,law ,Internal medicine ,Anti-Allergic Agents ,Perene ,medicine ,Humans ,030212 general & internal medicine ,Adverse effect ,Administration, Intranasal ,Rhinitis ,business.industry ,lcsh:Otorhinolaryngology ,lcsh:RF1-547 ,Perennial ,Clinical trial ,Meta-analysis ,Rinite ,Alérgica ,030228 respiratory system ,Otorhinolaryngology ,chemistry ,Controlled Clinical Trials as Topic ,business - Abstract
Introduction: Allergic rhinitis is a chronic inflammatory disease which affects 1 out of 6 individuals. Perennial allergic rhinitis accounts for 40% of AR cases. Ciclesonide is one of the relatively new intranasal steroid for allergic rhinitis. Objective: The purpose of this study was to evaluate the efficacy and safety of ciclesonide in the treatment of perennial allergic rhinitis. Methods: We searched Pubmed, Scientific Citation Index, Embase, Clinical Trial Registries for randomized controlled trials and Cochrane Central Register of Controlled Trials to find out the randomized controlled Trial comparing ciclesonide with placebo for PAR. Results: Eight studies were included. In comparison with placebo groups, ciclesonide groups significantly decreased Reflective Total Nasal Symptom Score (MD = −0.56; 95% CI −0.72 to 0.39, p
- Published
- 2019
- Full Text
- View/download PDF